Using denosumab to treat knee osteoarthritis
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
This study is testing whether denosumab, a medication usually used for osteoporosis, can help people with knee osteoarthritis feel better and slow down the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 45 Years to 75 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | denosumab |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06357741 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effects of denosumab, a medication commonly used for osteoporosis, on patients suffering from knee osteoarthritis. The study aims to explore the potential of denosumab to inhibit the RANKL-RANK pathway, which is implicated in the progression of knee osteoarthritis. With a significant portion of the elderly population affected by this condition, the study seeks to provide insights into a possible effective treatment option that could alleviate symptoms and potentially reverse disease progression. Participants will be monitored for their response to the treatment over the course of the study.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 45 to 75 who have been diagnosed with knee osteoarthritis and meet specific inclusion criteria.
Not a fit: Patients with mental illness, malignant tumors, or other significant health issues such as metabolic bone disease or diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with knee osteoarthritis, potentially reducing the need for knee replacement surgeries.
How similar studies have performed: While denosumab has been successfully used in treating osteoporosis, its application for knee osteoarthritis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" . * no drug contraindications . * aged between 45 and 75 . * committed to follow the research procedures, And cooperate with the •implementation of the whole process study . * the patient understands the relevant treatment process . * the patient has the ability to give informed consent . * The patient had not recently taken any medication that affected observation. * the subjects must meet all the inclusion criteria to be eligible to participate in the study . Exclusion Criteria: * mental illness . * patients with malignant tumors. * patients with other infectious diseases . * patients with metabolic bone disease, diabetes and hyperthyroidism. * patients who cannot actively cooperate in the treatment. * hypocalcemia.
Where this trial is running
Wuhan, Hubei
- Wuhan Union Hospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Tian Hongtao, Doctorate — Wuhan Union Medical College Hospital
- Study coordinator: Tian Hongtao, Doctorate
- Email: tianhongtao@vip.163.com
- Phone: 18627171618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.